While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis hasn't changed. Novo Nordisk is still a dominant player in a growing industry, ...

Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...